NM_007194.4(CHEK2):c.265A>C (p.Thr89Pro) AND Familial cancer of breast

Germline classification:: Uncertain significance (1 submission)
Last evaluated:: Aug 7, 2022
Review status:: 1 star out of maximum of 4 stars
criteria provided, single submitter

Somatic classification of clinical impact:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Somatic classification of oncogenicity:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Record status:: current
Accession:: RCV003116838.5

Allele description [Variation Report for NM_007194.4(CHEK2):c.265A>C (p.Thr89Pro)]

NM_007194.4(CHEK2):c.265A>C (p.Thr89Pro)

Gene:

CHEK2:checkpoint kinase 2 [Gene - OMIM - HGNC]

Variant type:

single nucleotide variant

Cytogenetic location:

22q12.1

Genomic location:

Preferred name:

NM_007194.4(CHEK2):c.265A>C (p.Thr89Pro)

HGVS:

NC_000022.11:g.28734457T>G
NG_008150.2:g.12410A>C
NM_001005735.2:c.265A>C
NM_001257387.2:c.-513A>C
NM_001349956.2:c.265A>C
NM_007194.4:c.265A>CMANE SELECT
NM_145862.2:c.265A>C
NP_001005735.1:p.Thr89Pro
NP_001336885.1:p.Thr89Pro
NP_009125.1:p.Thr89Pro
NP_665861.1:p.Thr89Pro
LRG_302t1:c.265A>C
LRG_302:g.12410A>C
LRG_302p1:p.Thr89Pro
NC_000022.10:g.29130445T>G

Protein change:

T89P

Molecular consequence:

NM_001257387.2:c.-513A>C - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
NM_001005735.2:c.265A>C - missense variant - [Sequence Ontology: SO:0001583]
NM_001349956.2:c.265A>C - missense variant - [Sequence Ontology: SO:0001583]
NM_007194.4:c.265A>C - missense variant - [Sequence Ontology: SO:0001583]
NM_145862.2:c.265A>C - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:: Familial cancer of breast
Synonyms:: Breast cancer, familial; Hereditary breast cancer
Identifiers:: MONDO: MONDO:0016419; MedGen: C0346153; OMIM: 114480

Recent activity

Clear Turn Off Turn On

Dyskinesia, Drug-Induced
Dyskinesia, Drug-Induced
Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and e...<br/>Year introduced: 1977

MeSH
D004409 (1)
MeSH
PUTATIVE PSEUDOGENE: RecName: Full=Putative cytochrome c oxidase subunit 7A3, mi...
PUTATIVE PSEUDOGENE: RecName: Full=Putative cytochrome c oxidase subunit 7A3, mitochondrial; AltName: Full=Cytochrome c oxidase subunit VIIa 3; Flags: Precursor
gi|8928009|sp|O60397.1|COX7S_HUMAN

Protein
LOC121376396 [Gigantopelta aegis]
LOC121376396 [Gigantopelta aegis]
Gene ID:121376396

Gene
LOC121367301 [Gigantopelta aegis]
LOC121367301 [Gigantopelta aegis]
Gene ID:121367301

Gene

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Help

Submission Accession	Submitter	Review Status (Assertion method)	Clinical Significance (Last evaluated)	Origin	Method	Citations
SCV003795514	Labcorp Genetics (formerly Invitae), Labcorp	criteria provided, single submitter (Invitae Variant Classification Sherloc (09022015))	Uncertain significance (Aug 7, 2022)	germline	clinical testing	PubMed (1) [See all records that cite this PMID]

Submission Accession

Submitter

Review Status
(Assertion method)

Clinical Significance
(Last evaluated)

Origin

Method

Citations

SCV003795514

Labcorp Genetics (formerly Invitae), Labcorp

criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))

Uncertain significance
(Aug 7, 2022)

germline

clinical testing

PubMed (1)
[See all records that cite this PMID]

Help

Summary from all submissions

Ethnicity	Origin	Affected	Individuals	Families	Chromosomes tested	Number Tested	Family history	Method
not provided	germline	unknown	not provided	not provided	not provided	not provided	not provided	clinical testing

Citations

PubMed

Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M; Invitae Clinical Genomics Group., Topper S.

Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11. Erratum in: Genet Med. 2020 Jan;22(1):240. doi: 10.1038/s41436-019-0624-9.

PubMed [citation]

PMID:: 28492532
PMCID:: PMC5632818

Details of each submission

From Labcorp Genetics (formerly Invitae), Labcorp, SCV003795514.3

#	Ethnicity	Individuals	Chromosomes Tested	Family History	Method	Citations
1	not provided	not provided	not provided	not provided	clinical testing	PubMed (1)

Description

In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. This variant has not been reported in the literature in individuals affected with CHEK2-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces threonine, which is neutral and polar, with proline, which is neutral and non-polar, at codon 89 of the CHEK2 protein (p.Thr89Pro).

#	Sample				Method		Observation
#	Origin	Affected	Number tested	Tissue	Purpose	Method	Individuals	Allele frequency	Families	Co-occurrences
1	germline	unknown	not provided	not provided	not provided		not provided	not provided	not provided	not provided

Last Updated: Sep 29, 2024

ClinVar

Relating variation to medicine